Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Liver Disorders

An Introduction to Liver Disorders

Supported by:
US Hepatology Partner
EU Hepatology Partner
Global Hepatology Partner
Mark CompleteCompleted
BookmarkBookmarked

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease driven by fat build-up and immune activation, often linked to obesity and diabetes. Emerging therapies target both metabolic and immune pathways, showing promise in reducing inflammation, improving liver function, and reversing fibrosis. These advances offer hope for better management of this complex disease.

Mark CompleteCompleted
BookmarkBookmarked

In this Future Leaders interview, Dr Moritz Peiseler shares how his work is reshaping our understanding of liver immunity through tools like intravital microscopy and AI-driven data analysis. He highlights the adaptive nature of immune cells in fibrotic tissue, the critical value of the clinician-scientist role, and the emerging potential of spatial and single-cell technologies. Dr Peiseler also offers thoughtful advice for young researchers aiming to bridge science and patient care.

Mark CompleteCompleted
BookmarkBookmarked

In this interview, EASL Secretary General Professor Debbie Shawcross discusses the growing burden of liver disease across Europe and the urgent need for early diagnosis, equitable care, and patient-centred approaches. She highlights how EASL is tackling these challenges through education, research, advocacy, and initiatives that bridge innovation and clinical practice to improve outcomes in hepatology.

Mark CompleteCompleted
BookmarkBookmarked

As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr Mitchell L Shiffman

Dr Mitchell L Shiffman explores the current and future management of primary biliary cholangitis

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Prof. Gideon Hirschfield, Prof. Sonja Ständer, Ms Michelle Clayton, Mrs Collette Thain MBE

A multidisciplinary team and a patient advocate discuss the management of cholestatic pruritus in primary biliary cholangitis (PBC).

Mark CompleteCompleted
BookmarkBookmarked

The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Palak Trivedi, Prof. Gideon Hirschfield

Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.

Developed by Touch
Coverage from: UEG Highlights

LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET ...

Developed by Touch
Coverage from: EASL Highlights

MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d'Hebron University Hospital, Barcelona, Spain) discusses the results from the ...

Developed by Touch
Coverage from: EASL Highlights

touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the ...

Coverage from: DDW Highlights

It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 ...

Coverage from: ACR Highlights

In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in ...

Load More...
Close Popup